US hospitals testing experimental therapies to prevent two common bacterial infections

(NIH/National Institute of Allergy and Infectious Diseases) NIAID-supported clinical sites in the US are participating in two ongoing international Phase 2 trials evaluating investigational antibody-based therapies aimed at preventing potentially antibiotic-resistant infections. By aligning the NIAID Antibacterial Resistance Leadership Group (ARLG) with a large international consortium leading the effort, the US investigators hope to enroll adult patients from 15 intensive care units in the tria...